Biotech Values

[DonShimoda]

It's not rocket science to see ARIA's been making higher lows on increasing volume for the last 12 months. The stock recently hit resistance at the upper BollBand and has been basically tracking the 20 DMA since then. At some point it will test the 50 DMA which will be a good re-entry point for those so inclined.

As far as there being no new data at ASH, I disagree. Prior to ASH I imagine most investors saw AP534 primarily as a phase 2/3 treatment focused on T315I. The CyR data presented at ASH confirms AP534 potential as a pan BCR-ABL inhibitor that is EQUALLY as effective as the current 2nd line treatments in CP CML. BUT AP534 also hits the mutations while tasigna and sprycel do not. I would expect to see a trial for pts who have failed gleevec and then randomize to either an AP534 arm or tasigna/sprycel arm. If the data presented holds up, the results should show AP534 has greater efficacy than either tasigna or sprycel which would position AP534 as the primary 2nd line option.